These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 14687421)

  • 21. Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone.
    Nyman JA
    Health Econ; 2011 Jan; 20(1):56-67. PubMed ID: 19946890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life--economic aspects.
    Jönsson B
    Scand J Prim Health Care Suppl; 1990; 1():93-6. PubMed ID: 2129233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility analysis of cochlear implants in Korea using different measures of utility.
    Lee HY; Park EC; Kim HJ; Choi JY; Kim HN
    Acta Otolaryngol; 2006 Aug; 126(8):817-23. PubMed ID: 16846923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based medicine, utilities, and quality of life.
    Brown MM; Brown GC; Sharma S; Garrett S
    Curr Opin Ophthalmol; 1999 Jun; 10(3):221-6. PubMed ID: 10537783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement, modeling and QALYs.
    Langley PC; McKenna SP
    F1000Res; 2020; 9():1048. PubMed ID: 33093950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.
    Fryback DG; Lawrence WF
    Med Decis Making; 1997; 17(3):276-84. PubMed ID: 9219187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuropharmacoeconomics].
    Chiu HC
    Acta Neurol Taiwan; 2004 Jun; 13(2):87-96. PubMed ID: 15478681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calculating QALYs, comparing QALY and DALY calculations.
    Sassi F
    Health Policy Plan; 2006 Sep; 21(5):402-8. PubMed ID: 16877455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
    Raisch DW
    Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilitarianism and the measurement and aggregation of quality--adjusted life years.
    Dolan P
    Health Care Anal; 2001; 9(1):65-76. PubMed ID: 11372576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QALY as evaluation tool in a health surveillance program.
    Esser A; Gube M; Schettgen T; Kraus T; Lang J
    Int J Hyg Environ Health; 2014 Mar; 217(2-3):399-404. PubMed ID: 24054544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Controversies around QALYs].
    Rogalewicz V; Barták M
    Vnitr Lek; 2017; 63(4):242-248. PubMed ID: 28520447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Setting Dead at Zero: Applying Scale Properties to the QALY Model.
    Roudijk B; Donders ART; Stalmeier PFM
    Med Decis Making; 2018 Aug; 38(6):627-634. PubMed ID: 29629848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QALYs and mental health care.
    Chisholm D; Healey A; Knapp M
    Soc Psychiatry Psychiatr Epidemiol; 1997 Feb; 32(2):68-75. PubMed ID: 9050347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.